Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi,Michiel S. Van der Heijden,Dmytro Trukhin,Avivit Peer,Howard Gurney,Boris Y. Alekseev,Francis X. Parnis,Raya Leibowitz,Maria De Santis,Petros Grivas,Jason Clark,Mihaela Munteanu, Ritesh Kataria,Calvin Jia,Arjun V. Balar,Ronald de Wit

BMC Cancer（2024）

Cited 0|Views5

No score

Abstract

Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumor effects of immune checkpoint inhibitors. Epacadostat is a potent and highly selective inhibitor of IDO1. In the phase I/II ECHO-202/KEYNOTE-037 study, epacadostat plus pembrolizumab resulted in a preliminary objective response rate (ORR) of 35

Translated text

Key words

IDO1,Epacadostat,PD-L1,PD1,Pembrolizumab,Urothelial carcinoma,Urinary tract neoplasms,Immune checkpoint inhibition,Immunotherapy,Randomized controlled study

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined